198 related articles for article (PubMed ID: 16555340)
1. Proteomics-driven progress in neurodegeneration research.
Fountoulakis M; Kossida S
Electrophoresis; 2006 Apr; 27(8):1556-73. PubMed ID: 16555340
[TBL] [Abstract][Full Text] [Related]
2. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform.
Pan S; Rush J; Peskind ER; Galasko D; Chung K; Quinn J; Jankovic J; Leverenz JB; Zabetian C; Pan C; Wang Y; Oh JH; Gao J; Zhang J; Montine T; Zhang J
J Proteome Res; 2008 Feb; 7(2):720-30. PubMed ID: 18186601
[TBL] [Abstract][Full Text] [Related]
3. Proteomics in Parkinson's disease: current trends, translational snags and future possibilities.
Srivastava G; Singh K; Tiwari MN; Singh MP
Expert Rev Proteomics; 2010 Feb; 7(1):127-39. PubMed ID: 20121482
[TBL] [Abstract][Full Text] [Related]
4. Proteomics- and transcriptomics-based screening of differentially expressed proteins and genes in brain of Wig rat: a model for attention deficit hyperactivity disorder (ADHD) research.
Hirano M; Rakwal R; Shibato J; Sawa H; Nagashima K; Ogawa Y; Yoshida Y; Iwahashi H; Niki E; Masuo Y
J Proteome Res; 2008 Jun; 7(6):2471-89. PubMed ID: 18457438
[TBL] [Abstract][Full Text] [Related]
5. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking.
Zabel C; Sagi D; Kaindl AM; Steireif N; Kläre Y; Mao L; Peters H; Wacker MA; Kleene R; Klose J
J Proteome Res; 2006 Aug; 5(8):1948-58. PubMed ID: 16889417
[TBL] [Abstract][Full Text] [Related]
6. [Proteomics: biomarker research in psychiatry].
Hünnerkopf R; Grassl J; Thome J
Fortschr Neurol Psychiatr; 2007 Oct; 75(10):579-86. PubMed ID: 17566964
[TBL] [Abstract][Full Text] [Related]
7. Relevance of protein nitration in brain injury: a key pathophysiological mechanism in neurodegenerative, autoimmune, or inflammatory CNS diseases and stroke.
Sarchielli P; Galli F; Floridi A; Floridi A; Gallai V
Amino Acids; 2003 Dec; 25(3-4):427-36. PubMed ID: 14661102
[TBL] [Abstract][Full Text] [Related]
8. Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection.
Cosimo Melcangi R; Garcia-Segura LM
Horm Behav; 2010 Jan; 57(1):2-11. PubMed ID: 19524584
[TBL] [Abstract][Full Text] [Related]
9. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF).
Maurer MH
Mass Spectrom Rev; 2010; 29(1):17-28. PubMed ID: 19116946
[TBL] [Abstract][Full Text] [Related]
10. Proteomic research in psychiatry.
Taurines R; Dudley E; Grassl J; Warnke A; Gerlach M; Coogan AN; Thome J
J Psychopharmacol; 2011 Feb; 25(2):151-96. PubMed ID: 20142298
[TBL] [Abstract][Full Text] [Related]
11. Protein expression overlap: more important than which proteins change in expression?
Zabel C; Andreew A; Mao L; Hartl D
Expert Rev Proteomics; 2008 Apr; 5(2):187-205. PubMed ID: 18466051
[TBL] [Abstract][Full Text] [Related]
12. Functional Genomics meets neurodegenerative disorders. Part II: application and data integration.
Hoerndli F; David DC; Götz J
Prog Neurobiol; 2005 Jun; 76(3):169-88. PubMed ID: 16169146
[TBL] [Abstract][Full Text] [Related]
13. Heat shock responses for understanding diseases of protein denaturation.
Kim HJ; Hwang NR; Lee KJ
Mol Cells; 2007 Apr; 23(2):123-31. PubMed ID: 17464187
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Hol EM; Fischer DF; Ovaa H; Scheper W
Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration.
Arboleda G; Morales LC; Benítez B; Arboleda H
Brain Res Rev; 2009 Mar; 59(2):333-46. PubMed ID: 18996148
[TBL] [Abstract][Full Text] [Related]
17. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases.
Sheta EA; Appel SH; Goldknopf IL
Expert Rev Proteomics; 2006 Feb; 3(1):45-62. PubMed ID: 16445350
[TBL] [Abstract][Full Text] [Related]
18. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease.
Polidori MC; Griffiths HR; Mariani E; Mecocci P
Amino Acids; 2007; 32(4):553-9. PubMed ID: 17273806
[TBL] [Abstract][Full Text] [Related]
19. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders].
Gabelle A; Roche S; Lehmann S
Rev Neurol (Paris); 2009 Mar; 165(3):213-22. PubMed ID: 18808768
[TBL] [Abstract][Full Text] [Related]
20. Clinical proteomics in neurodegenerative disorders.
Zetterberg H; Rüetschi U; Portelius E; Brinkmalm G; Andreasson U; Blennow K; Brinkmalm A
Acta Neurol Scand; 2008 Jul; 118(1):1-11. PubMed ID: 18279484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
